Literature DB >> 23780578

Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

Felix Mahfoud1, Christian Ukena, Roland E Schmieder, Bodo Cremers, Lars C Rump, Oliver Vonend, Joachim Weil, Martin Schmidt, Uta C Hoppe, Thomas Zeller, Axel Bauer, Christian Ott, Erwin Blessing, Paul A Sobotka, Henry Krum, Markus Schlaich, Murray Esler, Michael Böhm.   

Abstract

BACKGROUND: Catheter-based renal sympathetic denervation (RDN) reduces office blood pressure (BP) in patients with resistant hypertension according to office BP. Less is known about the effect of RDN on 24-hour BP measured by ambulatory BP monitoring and correlates of response in individuals with true or pseudoresistant hypertension. METHODS AND
RESULTS: A total of 346 uncontrolled hypertensive patients, separated according to daytime ambulatory BP monitoring into 303 with true resistant (office systolic BP [SBP] 172.2±22 mm Hg; 24-hour SBP 154±16.2 mm Hg) and 43 with pseudoresistant hypertension (office SBP 161.2±20.3 mm Hg; 24-hour SBP 121.1±19.6 mm Hg), from 10 centers were studied. At 3, 6, and 12 months follow-up, office SBP was reduced by 21.5/23.7/27.3 mm Hg, office diastolic BP by 8.9/9.5/11.7 mm Hg, and pulse pressure by 13.4/14.2/14.9 mm Hg (n=245/236/90; P for all <0.001), respectively. In patients with true treatment resistance there was a significant reduction with RDN in 24-hour SBP (-10.1/-10.2/-11.7 mm Hg, P<0.001), diastolic BP (-4.8/-4.9/-7.4 mm Hg, P<0.001), maximum SBP (-11.7/-10.0/-6.1 mm Hg, P<0.001) and minimum SBP (-6.0/-9.4/-13.1 mm Hg, P<0.001) at 3, 6, and 12 months, respectively. There was no effect on ambulatory BP monitoring in pseudoresistant patients, whereas office BP was reduced to a similar extent. RDN was equally effective in reducing BP in different subgroups of patients. Office SBP at baseline was the only independent correlate of BP response.
CONCLUSIONS: RDN reduced office BP and improved relevant aspects of ambulatory BP monitoring, commonly linked to high cardiovascular risk, in patients with true-treatment resistant hypertension, whereas it only affected office BP in pseudoresistant hypertension.

Entities:  

Keywords:  ambulatory blood pressure monitoring; hypertension resistant to conventional therapy; sympathectomy

Mesh:

Year:  2013        PMID: 23780578     DOI: 10.1161/CIRCULATIONAHA.112.000949

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  68 in total

Review 1.  The rise, fall, and possible resurrection of renal denervation.

Authors:  Rajiv Gulati; Claire E Raphael; Manuela Negoita; Stuart J Pocock; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

Review 2.  Renal denervation: effects on atrial electrophysiology and arrhythmias.

Authors:  Dominik Linz; Arne van Hunnik; Christian Ukena; Sebastian Ewen; Felix Mahfoud; Stephan H Schirmer; Matthias Lenski; Hans-Ruprecht Neuberger; Ulrich Schotten; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2014-03-29       Impact factor: 5.460

3.  Hypertension: Further EnligHTNment on renal sympathetic denervation.

Authors:  Bryony M Mearns
Journal:  Nat Rev Cardiol       Date:  2013-07-09       Impact factor: 32.419

Review 4.  Review of the state of renal nerve ablation for patients with severe and resistant hypertension.

Authors:  Vinay Gulati; William B White
Journal:  J Am Soc Hypertens       Date:  2013-08-15

5.  Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry.

Authors:  Britta Vogel; Michael Kirchberger; Martin Zeier; Felicitas Stoll; Benjamin Meder; Daniel Saure; Martin Andrassy; Oliver J Mueller; Stefan Hardt; Vedat Schwenger; Anna Strothmeyer; Hugo A Katus; Erwin Blessing
Journal:  Clin Res Cardiol       Date:  2013-10-15       Impact factor: 5.460

6.  Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation.

Authors:  Oliver Dörr; Sebastian Ewen; Christoph Liebetrau; Helge Möllmann; Luise Gaede; Dominik Linz; Mathias Hohl; Christian Troidl; Timm Bauer; Michael Böhm; Christian Hamm; Felix Mahfoud; Holger Nef
Journal:  Clin Res Cardiol       Date:  2015-05-26       Impact factor: 5.460

Review 7.  Type 2 diabetes mellitus and hypertension: an update.

Authors:  Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 8.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

9.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

10.  Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea).

Authors:  B-K Kim; M Böhm; F Mahfoud; G Mancia; S Park; M-K Hong; H-S Kim; S-J Park; C G Park; K B Seung; H-C Gwon; D-J Choi; T H Ahn; C J Kim; H M Kwon; M Esler; Y S Jang
Journal:  J Hum Hypertens       Date:  2015-07-09       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.